A3 HCl | CAS#78957-85-4 | PKA inhibitor

MedKoo Cat#: 527839 | Name: A3 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A3 HCl is an inhibitor of PKA, PKC, and casein kinase I and II, and MLCK.

Chemical Structure

A3 HCl

CAS#78957-85-4

Theoretical Analysis

MedKoo Cat#: 527839

Name: A3 HCl

CAS#: 78957-85-4

Chemical Formula: C12H14Cl2N2O2S

Exact Mass: 320.0153

Molecular Weight: 321.22

Elemental Analysis: C, 44.87; H, 4.39; Cl, 22.07; N, 8.72; O, 9.96; S, 9.98

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

A3 HCl

IUPAC/Chemical Name

N-(2-Aminoethyl)-5-chloronaphthalene-1-sulfonamide hydrochloride

InChi Key

VWAGIWCLJAQLAL-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H13ClN2O2S.ClH/c13-11-5-1-4-10-9(11)3-2-6-12(10)18(16,17)15-8-7-14;/h1-6,15H,7-8,14H2;1H

SMILES Code

O=S(C1=C2C=CC=C(Cl)C2=CC=C1)(NCCN)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 321.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gessi S, Bencivenni S, Battistello E, Vincenzi F, Colotta V, Catarzi D, Varano F, Merighi S, Borea PA, Varani K. Inhibition of A(2A) Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. Front Pharmacol. 2017 Dec 1;8:888. doi: 10.3389/fphar.2017.00888. eCollection 2017. PubMed PMID: 29249971; PubMed Central PMCID: PMC5716981. 2: Agunloye OM, Oboh G. Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil. J Complement Integr Med. 2017 Sep 22;15(1). pii: /j/jcim.2018.15.issue-1/jcim-2017-0016/jcim-2017-0016.xml. doi: 10.1515/jcim-2017-0016. PubMed PMID: 28941354. 3: Krishna KD, Pradip ST, Navin SR. Preparation and Optimization of Fast Dissolving Film of Naratr iptan Hydrochloride. Recent Pat Drug Deliv Formul. 2017;11(2):124-131. doi: 10.2174/1872211311666170213105001. PubMed PMID: 28201962. 4: Kohno K, Ohashi E, Sano O, Kusano H, Kunikata T, Arai N, Hanaya T, Kawata T, Nishimoto T, Fukuda S. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015 Jan 20;12(1):2. doi: 10.1186/s12950-014-0045-0. eCollection 2015. PubMed PMID: 25632271; PubMed Central PMCID: PMC4308844. 5: Vignozzi L, Filippi S, Comeglio P, Cellai I, Morelli A, Rastrelli G, Maneschi E, Mannucci E, Maggi M. Metformin in vitro and in vivo increases adenosine signaling in rabbit corpora cavernosa. J Sex Med. 2014 Jul;11(7):1694-708. doi: 10.1111/jsm.12572. Epub 2014 May 20. PubMed PMID: 24844317. 6: Sun C, Li J, Gu J, Liu J, Huang B. Proteomic studies of multiple myeloma in RPMI8226 cell line treated with bendamustine. J BUON. 2013 Oct-Dec;18(4):996-1005. PubMed PMID: 24344029. 7: Gessi S, Merighi S, Stefanelli A, Fazzi D, Varani K, Borea PA. A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. Pharmacol Res. 2013 Oct;76:157-70. doi: 10.1016/j.phrs.2013.08.002. Epub 2013 Aug 19. PubMed PMID: 23969284. 8: Baraldi PG, Saponaro G, Romagnoli R, Aghazadeh Tabrizi M, Baraldi S, Moorman AR, Cosconati S, Di Maro S, Marinelli L, Gessi S, Merighi S, Varani K, Borea PA, Preti D. Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A₃ adenosine receptor antagonists. J Med Chem. 2012 Jun 14;55(11):5380-90. doi: 10.1021/jm300323t. Epub 2012 May 18. PubMed PMID: 22568637. 9: Pacheco MJ, Santos V, Ciríaco L, Lopes A. Electrochemical degradation of aromatic amines on BDD electrodes. J Hazard Mater. 2011 Feb 28;186(2-3):1033-41. doi: 10.1016/j.jhazmat.2010.11.108. Epub 2010 Dec 3. PubMed PMID: 21168968. 10: Sander C, Arns M, Olbrich S, Hegerl U. EEG-vigilance and response to stimulants in paediatric patients with attention deficit/hyperactivity disorder. Clin Neurophysiol. 2010 Sep;121(9):1511-8. doi: 10.1016/j.clinph.2010.03.021. Epub 2010 Apr 9. PubMed PMID: 20382071. 11: Shayeda, Gannu R, Palem CR, Rao YM. Development of novel bioadhesive buccal formulation of diltiazem: in vitro and in vivo characterization. PDA J Pharm Sci Technol. 2009 Sep-Oct;63(5):401-8. PubMed PMID: 20158046. 12: Mamatha T, Venkateswara Rao J, Mukkanti K, Ramesh G. Development of matrix type transdermal patches of lercanidipine hydrochloride: physicochemical and in-vitro characterization. Daru. 2010;18(1):9-16. PubMed PMID: 22615587; PubMed Central PMCID: PMC3232088. 13: Donoso MV, Aedo F, Huidobro-Toro JP. The role of adenosine A2A and A3 receptors on the differential modulation of norepinephrine and neuropeptide Y release from peripheral sympathetic nerve terminals. J Neurochem. 2006 Mar;96(6):1680-95. PubMed PMID: 16539684. 14: Pugliese AM, Coppi E, Spalluto G, Corradetti R, Pedata F. A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. Br J Pharmacol. 2006 Mar;147(5):524-32. PubMed PMID: 16415905; PubMed Central PMCID: PMC1616978. 15: Das S, Tosaki A, Bagchi D, Maulik N, Das DK. Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther. 2005 Aug;314(2):762-9. Epub 2005 May 5. PubMed PMID: 15879002. 16: Fenton RA, Flynn A, Shodeinde A, Smith CP, Schnermann J, Knepper MA. Renal phenotype of UT-A urea transporter knockout mice. J Am Soc Nephrol. 2005 Jun;16(6):1583-92. Epub 2005 Apr 13. PubMed PMID: 15829709; PubMed Central PMCID: PMC1435686. 17: Das S, Cordis GA, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H328-35. Epub 2004 Sep 2. PubMed PMID: 15345477. 18: Adjene JO, Agoreyo FO. Effects of halofantrine hydrochloride (halfan) on the histology of the ovary of mature female Wistar rats. Afr J Reprod Health. 2003 Apr;7(1):113-20. PubMed PMID: 12816318. 19: Smith SR, Denhardt G, Terminelli C. A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA. Eur J Pharmacol. 2002 Dec 13;457(1):57-69. PubMed PMID: 12460644. 20: Schulte G, Fredholm BB. Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol. 2002 Nov;62(5):1137-46. PubMed PMID: 12391277.